<DOC>
	<DOCNO>NCT03066739</DOCNO>
	<brief_summary>The purpose study evaluate whether use ultra-low dose naloxone , opioid antagonist , potential block remifentanil-induced hyperalgesia tolerance follow surgery . There 3 study group : ( 1 ) low dose remifentanil ( LO , 0.1 micrograms/kg/mL ) , ( 2 ) high dose remifentanil ( 0.4 mg ) combine placebo ( HI , 0.4 micrograms/kg/mL ) , ( 3 ) high dose remifentanil ( 0.4 mg ) combine ultra-low dose naloxone ( HN , 0.004 micrograms/kg/mL naloxone ) . The hypothesis study occurrence remifentanil-induced hyperalgesia ( low score mechanical pain threshold ) HN group lower HI group .</brief_summary>
	<brief_title>Effect Ultra-low Dose Naloxone Remifentanil-Induced Hyperalgesia</brief_title>
	<detailed_description>Purpose : Opioid antagonist ultra-low dos use opioid agonist prevent limit opioid tolerance . Remifentanil , rapid onset/offset opioid often use anesthesia adjunct intraoperatively , associate development hyperalgesia opioid tolerance postoperatively . Opioid-induced hyperalgesia ( OIH ) induce remifentanil intraoperatively may factor contribute increase postoperative pain well difficulty control pain . The purpose study evaluate whether ultra-low dose naloxone , opioid antagonist , could block remifentanil-induced hyperalgesia tolerance follow surgery . This research help elucidate degree OIH surgery involve remifentanil determine new technique employ decrease remifentanil-induced OIH . By mitigate OIH , patient decrease postoperative pain increase patient satisfaction UCI hospital technique employ . There 3 study group : ( 1 ) low dose remifentanil ( LO , 0.1 micrograms/kg/mL ) , ( 2 ) high dose remifentanil ( 0.4 mg ) combine placebo ( HI , 0.4 micrograms/kg/mL ) , ( 3 ) high dose remifentanil ( 0.4 mg ) combine ultra-low dose naloxone ( HN , 0.004 micrograms/kg/mL naloxone ) . Background : Opioid-induced hyperalgesia paradoxical increase pain sensitivity follow opioid exposure . The mechanism likely due alteration opioid receptor signal disruption G-protein couple opioid-induced activation hypertrophy spinal glial cell ( gliosis ) . Opioid-induced hyperalgesia note many different opioids , well document hyperalgesic effect remifentanil . Various agent use attempt reduce development hyperalgesia follow remifentanil . While report effect ultra-low dose naloxone opioid-induced hyperalgesia , recent evidence emerge regard use pain management . Ultra-low dose naloxone show prevent remifentanil-induced pain hypersensitivity ( allodynia hyperalgesia ) rat . However , little study reduce adverse effect remifentanil naloxone human subject . Existing knowledge previous research : Attempts make various agent reduce development tolerance hyperalgesia follow remifentanil . Postoperative hyperalgesia prevention study ketamine , Magnesium , Gabapentin , Clonidine , Lornoxicam , Dextromethorphan , Paracetamol , Morphine , Dexmedetomidine , Adenosine , COX inhibitor , Amantadine , Nitrous oxide , Fentanyl , Pregabalin , Buprenorphine , Midazolam , Dexamethasone . Relevant current hypothesis report concomitant administration ultra-low dose naloxone naltrexone remifentanil prevent OIH . However , study reduce adverse effect remifentanil ultra-low dose naloxone human subject . While traditional role opiate antagonist case opioid overmedication , recent evidence emerge regard use pain management . Gan et al . 1997 use ultra-low dose naloxone infusion ( 0.00025 mg/kg/h 0.001 mg/kg/h ) postoperative patient receive IV morphine via patient-controlled analgesia ( PCA ) device . Good pain relief experience group , however consumption PCA morphine significantly reduce patient receive low infusion naloxone opioid-induced side effect ( nausea , vomit , pruritus ) reduce naloxone dose . Naloxone and/or naltrexone ultra-low dos may enhance analgesic effect opioids , enhance antinociceptive effect methadone , decrease block development opioid tolerance rodent . The combination oxycodone ultra-low dose antagonist naltrexone singular oral medication , Oxytrex , develop prevent development tolerance treatment moderate severe chronic pain . Aguado et . al . 2013 recently evaluate effect opioid antagonist , naloxone , remifentanil-induced tolerance hyperalgesia rat . Hyperalgesia consider decrease mechanical nociceptive threshold ( von Frey ) , opioid tolerance consider decrease sevoflurane MAC reduction remifentanil . An ultra-low dose naloxone able block remifentanil-induced hyperalgesia MAC increase associate hyperalgesia , change opioid tolerance inhale anesthesia .</detailed_description>
	<mesh_term>Hyperalgesia</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>Subjects provide write informed consent . Age 18 year old old ( upper age limit inclusion ) Gender : male female . Surgery : Posterior spinal fusion Allergy opiates Chronic pain primary indication surgery Psychiatric illness History substance abuse problem include alcohol &amp; /or cannabis BMI &gt; 35 Subjects 18 year age . Subject without capacity give write informed consent . 8 . Female subject pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>